Skip to Content
Merck
All Photos(2)

Key Documents

HNS1MAG-95K

Millipore

MILLIPLEX® Human Neuroscience Magnetic Bead Panel 1 - Neuroscience Multiplex Assay

allows quantitative multiplex detection of multiple analytes simultaneously

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.47


To order a Milliplex® kit, please search for your analyte of interest.

Quality Level

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 107%
(DJ1)

accuracy: 108%
(a-Synuclein)

accuracy: 123%
(TG2)

standard curve range: 12-50,000 pg/mL
(GFAP)

standard curve range: 15-60,000 pg/mL
(NSE)

standard curve range: 20-80,000 pg/mL
(UCHL1)

standard curve range: 244-1,000,000 pg/mL
(alpha-synuclein)

standard curve range: 61-250,000 pg/mL
(DJ1)

standard curve range: 61-250,000 pg/mL
(TG2)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

ambient

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
HNDG4MAG-36KHND3MAG-39KHNS2MAG-95K
manufacturer/tradename

Milliplex®

manufacturer/tradename

Milliplex®

manufacturer/tradename

Milliplex®

manufacturer/tradename

Milliplex®

assay range

accuracy: 107%
(DJ1), accuracy: 123%
(TG2), standard curve range: 15-60,000 pg/mL
(NSE), standard curve range: 244-1,000,000 pg/mL
(alpha-synuclein), standard curve range: 61-250,000 pg/mL
(TG2), accuracy: 108%
(a-Synuclein), standard curve range: 20-80,000 pg/mL
(UCHL1), standard curve range: 12-50,000 pg/mL
(GFAP), standard curve range: 61-250,000 pg/mL
(DJ1)

assay range

accuracy: 84-108%, standard curve range: 14-10,000 pg/mL
(S100B), standard curve range: 21-15,000 pg/mL
(sRAGE), standard curve range: 27-20,000 pg/mL
(Amyloid β42), standard curve range: 3-2,500 pg/mL
(Amyloid β40), standard curve range: 7-5,000 pg/mL
(GDNF)

assay range

accuracy: 69-92%
(Cerebrospinal fluid (CSF)), accuracy: 71-107%
(Serum), standard curve range: 0.03-25 ng/mL
(SOD2), standard curve range: 0.04-30 ng/mL
(Kallikrein-6), standard curve range: 0.04-30 ng/mL
(SOD1), standard curve range: 0.08-60 ng/mL
(Contactin-1), standard curve range: 0.14-100 ng/mL
(Osteopontin (OPN)), standard curve range: 1.37-1,000 ng/mL
(AGT), standard curve range: 4.12-3,000 ng/mL
(Fetuin A)

assay range

accuracy: 124%
(Neurogranin), accuracy: 84%
(FABP3), accuracy: 85%
(ApoE4), accuracy: 94%
(TREM2), accuracy: 97%
(Angiogenin), sensitivity: 11.0 pg/mL
(MinDC + 2SD; TREM2), sensitivity: 14.3 pg/mL
(MinDC + 2SD; FABP3), sensitivity: 162.8 pg/mL
(MinDC + 2SD; ApoE4), sensitivity: 19.9 pg/mL
(MinDC + 2SD; Neurogranin), sensitivity: 5.8 pg/mL
(MinDC + 2SD; Angiogenin), sensitivity: 6.1 pg/mL
(MinDC + 2SD; Ferritin), standard curve range: 15-50,000 pg/mL
(TREM2), standard curve range: 2-10,000 pg/mL
(Angiogenin), standard curve range: 24-100,000 pg/mL
(FABP3), standard curve range: 244-1,000,000 pg/mL
(ApoE4), standard curve range: 5-20,000 pg/mL
(Neurogranin), standard curve range: 6-25,000 pg/mL
(Ferritin), inter-assay cv: <10%
intra-assay cv: <5%
(Angiogenin), inter-assay cv: <10%
intra-assay cv: <5%
(FABP3), inter-assay cv: <10%
intra-assay cv: <5%
(TREM2), inter-assay cv: <15%
intra-assay cv: <10%
(Ferritin), inter-assay cv: <15%
intra-assay cv: <10%
(Neurogranin), inter-assay cv: <15%
intra-assay cv: <5%
(ApoE4)

Quality Level

200

Quality Level

200

Quality Level

200

Quality Level

-

technique(s)

multiplexing: suitable

technique(s)

multiplexing: suitable

technique(s)

multiplexing: suitable

technique(s)

multiplexing: suitable

shipped in

ambient

shipped in

wet ice

shipped in

wet ice

shipped in

-

General description

Neurological dysfunction may be initiated by a broad spectrum of diseases, as well as physical injury to the brain or spinal cord. Numerous potential biomarkers of neurological dysfunction have been identified. The ability to perform multiplex analysis of these biomarkers offers a valuable research tool to better understand this area of neuroscience.

MILLIPLEX® Human Neuroscience Bead Panel 1 is a 6-plex kit to be used for the simultaneous quantification of any or all of the following analytes in cerebrospinal fluid (CSF) samples: α-Synuclein, DJ1/PARK7, Glial fibrillary acidic protein (GFAP), Neuron specific enolase (NSE), Transglutaminase 2 (TGM2), and Ubiquitin carboxyl-terminal esterase L1 (UCHL1/PARK5).

Panel Type: Neuroscience

Specificity

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

  • Analytes: GFAP, NSE, α-Synuclein, PARK5, Transglutaminase 2 (TGM2)
  • Recommended Sample type: CSF
  • Recommended Sample dilution: Neat
  • Assay Run Time: Overnight or one day
  • Research Category: Neuroscience

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Packaging

Everything you need in a single kit.

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Other Notes

Sensitivity: See protocol for sensitivities of individual analytes

Legal Information

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Daniela Diaz-Lucena et al.
Journal of neurology, 267(9), 2567-2581 (2020-05-07)
Differential diagnosis of neurodegenerative dementia is currently supported by biomarkers including cerebrospinal fluid (CSF) tests. Among them, CSF total-tau (t-tau), phosphorylated tau (p-tau) and β-amyloid42 (Aβ42) are considered core biomarkers of neurodegeneration. In the present work, we hypothesize that simultaneous
Martin Trapecar et al.
Science advances, 7(5) (2021-01-31)
Slow progress in the fight against neurodegenerative diseases (NDs) motivates an urgent need for highly controlled in vitro systems to investigate organ-organ- and organ-immune-specific interactions relevant for disease pathophysiology. Of particular interest is the gut/microbiome-liver-brain axis for parsing out how

Related Content

MILLIPLEX® multiplex immunoassays detect Alzheimer's biomarkers in neuroscience research using high sensitivity technology.

MILLIPLEX® multiplex immunoassays detect Alzheimer's biomarkers in neuroscience research using high sensitivity technology.

MILLIPLEX® multiplex immunoassays detect Alzheimer's biomarkers in neuroscience research using high sensitivity technology.

MILLIPLEX® multiplex immunoassays detect Alzheimer's biomarkers in neuroscience research using high sensitivity technology.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service